Skip to main content

Table 2 Vaccines based on six Leishmania pathoantigens (H2A, H2B, H3, H4, A2 and HSP70)

From: Mitigating an undesirable immune response of inherent susceptibility to cutaneous leishmaniosis in a mouse model: the role of the pathoantigenic HISA70 DNA vaccine

Antigen Targeted disease Animal model Delivery system Result Reference
H2A/H2B/H3/H4 CL BALB/c DNA vaccine Protection [34]
N-terminal part-H2B CL BALB/c Protein + CpG Protection [52]
H2A/H2B/H3/H4 CL BALB/c Ag-loaded DCs Long-lasting protection [53]
H2A/H3, H2A/H4, H2B/H3, H2B/H4 CL BALB/c DNA vaccine Partial protection [40]
H2A/H2B, H3/H4 CL BALB/c DNA vaccine Partial protection [54]
H1/H2A/H2B/H3/H4 + 5 more Ags VL Dog DNA vaccine Partial protection (DLN) [55]
H2A/H2B/H3/H4 VL BALB/c DNA vaccine No protection [56]
H2A/H2B/H3/H4 VL BALB/c Ag-loaded DCs Partial protection [56]
A2 CL BALB/c Protein + IL-12 Partial protection [57]
A2 CL/VL BALB/c DNA vaccine Partial protection [58]
A2 VL BALB/c DNA vaccine Partial protection (liver) [59]
A2 VL BALB/c Protein + P. acnes Protection (liver) [60]
A2 VL Dog Protein + saponine Partial protection [61]
A2 VL BALB/c A2-Adenovirus Protection [62]
A2 VL BALB/c L. tarentolae Protection [63]
A2 VL BALB/c Live bacteria Partial protection [64]
HSP70 CL BALB/c Primeboost No protection [65]
HSP70 + HSP83 VL BALB/c Protein ± ALD/MPLA Protection (liver) [66]
GP63 + HSP70 VL BALB/c DNA vaccine Protection [67]
GP63 + HSP70 VL BALB/c Protein Protection [68]